BIIB|Analyst Targets
BIIB|Company Info
BIIB|Insider Trading
BIIB|Fundamentals
BIIB|Earnings Snapshot
EPS
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q3'26 | $2.02 | - | - |
| Q2'26 | $2.03 | $3.60 | +77.4% |
| Q1'26 | $2.95 | $3.57 | +20.9% |
| Q4'25 | $1.63 | $1.99 | +22.4% |
| Q3'25 | $3.88 | $4.81 | +23.9% |
| Q2'25 | $3.88 | $5.47 | +41.0% |
Revenue
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q3'26 | $2.7B | - | - |
| Q2'26 | $2.5B | $2.7B | +9.3% |
| Q1'26 | $2.2B | $2.5B | +10.2% |
| Q4'25 | $2.2B | $2.3B | +1.4% |
| Q3'25 | - | $2.5B | - |
| Q2'25 | - | $2.6B | - |
BIIB|Monthly Returns
Market Data
BIIB Stock Snapshot
- Market cap
- 33.83B
- P/E ratio
- 40.5
- Day range
- $228.00 – $233.90
- News sentiment
- 48/100 · Neutral
- Analyst target
- $243.98 (+4.9%)
- Consensus
- Buy · 44 analysts
BIIB is trading with the trend behind it, which is what pushes the technical read bullish. In Healthcare, names this size usually take direction from sector flows before company-level news.
Reverse DCF
What growth is priced into BIIB?
At today's price, Biogen Inc. needs to grow free cash flow about 0.5% a year for the next 10 years to justify its valuation at a 7.72% cost of capital. Over its actual history it has compounded free cash flow at 5.1% a year, so the market is asking for 4.6 percentage points below its own delivered rate. On that basis BIIB looks priced below what its own growth record supports.
- Implied FCF growth
- 0.5%
- Historical FCF CAGR
- 5.1%
- Growth gap
- -4.6 pts
- Verdict
- CHEAP
- Discount rate (WACC)
- 7.72%
- Beta
- 0.65
Behaviour On Record
What BIIB's own history says about today's numbers
- Realized volatility (21d)
- 22.4% 23rd pct
- Below its peak
- -47.1%
- vs 200-day average
- +16.5%
- Up days (1y)
- 53%
Biogen Inc. is currently running 22.4% annualised volatility over the last 21 sessions. Measured against BIIB's own 13 years of daily returns rather than a market-wide average, that is the 23rd percentile — unusually subdued by its own history, against a typical reading of 29.1%. The distinction matters because a number that looks calm for one stock is turbulent for another, and the absolute figure on its own tells you neither.
BIIB is trading -47.1% below its running peak. Across 12 full years on file, its median worst-drawdown-in-a-year was -31.0%, and the deepest was -46.2% in 2021. The current drawdown is already deeper than this stock's typical annual low point, which puts it in the part of its range where past recoveries began — and where past declines also continued.
Price sits +16.5% from its 200-day moving average. Against every other day in its history, that gap ranks at the 85th percentile — a wider gap than this stock usually carries. Over the past year BIIB closed higher on 53% of sessions, and it is currently 1 session into a rising streak.
On October specifically: over 14 years of records, BIIB finished the month higher 5 of 14 times, with a median return of -1.7% and an average of -1.1%. Its strongest month historically has been November at +2.1% on average, its weakest March at -4.7%. Seasonality is a weak signal on its own — a decade is a small sample and regimes change — but it is a real distribution rather than a rule of thumb.
Overnight risk is measurable too: BIIB has opened more than 2% away from the prior close in 109 of 3,267 sessions (3.3% of the time), with the largest gaps running +5.7% and -30.7%. For anyone holding through an event, that rate is a better guide to overnight exposure than the intraday range.
Across the last 3 dated reports on file, BIIB moved an average of 3.1% in the session after earnings, closing higher 0 of those 3 times, with a median move of -3.6% and a largest of -3.8%.
All figures computed from 3,269 daily closes between 2013-10-15 and 2026-10-14, split-adjusted, recomputed daily. Percentiles are against BIIB's own 13-year history, not a peer group or index.
Sector Rotation
Is money rotating into or out of BIIB's sector?
Biogen Inc. sits in the Health Care sector, currently ranked 2nd of 12 GICS sectors by relative-strength rotation score (leading).
- Sector rank
- #2 of 12
- Sector state
- Leading
- Sector rotation score
- 91
Analyst Rating Changes
Are analysts turning bullish or bearish on BIIB?
JP Morgan most recently upgraded Biogen Inc. to Overweight on Oct 12, 2026 with a price target of $300 (from $210). Over the last 90 days, coverage has run 2 upgrades against 0 downgrades, a net bullish lean.
- Latest action
- JP Morgan — Overweight
- 90-day upgrades
- 2
- 90-day downgrades
- 0
- Net rating momentum
- +2
Peers & ETF holders
BIIB peers & ETF holders
Drug Manufacturers - GeneralMarket cap · today
News Sentiment Analysis
Sentiment gathered from recent headlines
Recent News Coverage
Most recent articles, ranked by recency (click to expand).
Technical Analysis
Real-time indicators across multiple timeframes
| Manager | Trend | Shares Held | % of Co. | Position Value | Filed |
|---|---|---|---|---|---|
| FMR LLC (Fidelity) | ▲ Buy | 18,217,239 | 12.36% | $3.94B | 2026-08-13 |
| BlackRock, Inc. | ▲ Buy | 15,985,736 | 10.84% | $3.45B | 2026-08-07 |
| Vanguard Group Inc | ▲ Buy | 17,447,092 | 11.84% | $3.07B | 2026-01-29 |
| Geode Capital Management, LLC | ▲ Buy | 4,449,295 | 3.02% | $957.94M | 2026-08-12 |
| Wellington Management Group LLP | ▲ Buy | 3,117,469 | 2.11% | $673.56M | 2026-08-14 |
| Norges Bank | ▼ Sell | 2,580,033 | 1.75% | $557.44M | 2026-08-12 |
| Morgan Stanley | ▲ Buy | 2,411,271 | 1.64% | $520.98M | 2026-08-13 |
| AQR Capital Management LLC | ▲ Buy | 1,936,859 | 1.31% | $416.93M | 2026-08-14 |
| JPMorgan Chase & Co | ▼ Sell | 1,823,140 | 1.24% | $394.95M | 2026-08-12 |
| Invesco Ltd. | ▲ Buy | 1,803,944 | 1.22% | $389.76M | 2026-08-14 |
| Northern Trust Corp | ▼ Sell | 1,429,490 | 0.97% | $308.86M | 2026-08-13 |
| Goldman Sachs Group Inc | ▲ Buy | 1,230,390 | 0.83% | $265.84M | 2026-08-14 |
| Bank of America Corp | ▼ Sell | 1,116,228 | 0.76% | $241.17M | 2026-08-14 |
| Citigroup Inc | ▲ Buy | 734,517 | 0.50% | $158.70M | 2026-08-03 |
| Citadel Advisors LLC | ▲ Buy | 418,356 | 0.28% | $90.39M | 2026-09-02 |
| Fisher Asset Management, LLC | ▲ Buy | 338,018 | 0.23% | $73.03M | 2026-08-04 |
| Gotham Asset Management, LLC | ▼ Sell | 279,900 | 0.19% | $60.48M | 2026-08-14 |
| Balyasny Asset Management L.P. | ▼ Sell | 265,090 | 0.18% | $57.28M | 2026-08-14 |
| Man Group plc | ▼ Sell | 196,222 | 0.13% | $42.40M | 2026-08-14 |
| AllianceBernstein L.P. | ▲ Buy | 214,975 | 0.15% | $39.41M | 2026-08-14 |
| Palo Alto Investors LP | ▼ Sell | 140,279 | 0.10% | $30.31M | 2026-08-19 |
| Adage Capital Partners GP, L.L.C. | ▼ Sell | 129,599 | 0.09% | $28.00M | 2026-08-14 |
| Wells Fargo & Company | ▲ Buy | 128,664 | 0.09% | $27.80M | 2026-08-14 |
| Point72 Asset Management, L.P. | ▼ Sell | 88,149 | 0.06% | $19.05M | 2026-08-14 |
| Renaissance Technologies LLC | ▼ Sell | 77,744 | 0.05% | $16.80M | 2026-08-13 |
| Member | Chamber | State | Type | Amount | Traded | Filed |
|---|---|---|---|---|---|---|
| Maria Elvira Salazar | House | FL27 | ▼ Sell | $1K - $15K | 2026-09-24 | 2026-10-07 |
| Kevin Hern | House | OK01 | ▼ Sell | $1K - $15K | 2026-08-18 | 2026-09-01 |
| Gilbert Cisneros | House | CA31 | ▲ Buy | $1K - $15K | 2026-06-05 | 2026-07-02 |
| Maria Elvira Salazar | House | FL27 | ▼ Sell | $15K - $50K | 2026-06-02 | 2026-07-07 |
| Maria Elvira Salazar | House | FL27 | ▲ Buy | $1K - $15K | 2026-05-12 | 2026-06-08 |
| Maria Elvira Salazar | House | FL27 | ▲ Buy | $1K - $15K | 2026-05-11 | 2026-06-08 |
| Alan Armstrong | Senate | OK | ▲ Buy | $1K - $15K | 2026-03-27 | 2026-07-21 |
| Gilbert Cisneros | House | CA31 | ▲ Buy | $1K - $15K | 2026-01-30 | 2026-02-13 |
| Rob Bresnahan | House | PA08 | ▲ Buy | $1K - $15K | 2025-05-15 | 2025-06-09 |
| Rob Bresnahan | House | PA08 | ▼ Sell | $1K - $15K | 2025-04-08 | 2025-05-08 |
| Rob Bresnahan | House | PA08 | ▲ Buy | $1K - $15K | 2025-02-25 | 2025-03-27 |
| Sheldon Whitehouse | Senate | RI | ▼ Sell | $1K - $15K | 2019-03-22 | 2019-04-17 |
| Sheldon Whitehouse | Senate | RI | ▼ Sell | $1K - $15K | 2018-01-08 | 2018-02-13 |
| Sheldon Whitehouse | Senate | RI | ▼ Sell | $1K - $15K | 2016-12-23 | 2017-01-11 |
| Sheldon Whitehouse | Senate | RI | ▼ Sell | $15K - $50K | 2016-12-13 | 2017-01-11 |
| Sheldon Whitehouse | Senate | RI | ▲ Buy | $1K - $15K | 2015-08-28 | 2015-09-24 |
| Sheldon Whitehouse | Senate | RI | ▲ Buy | $1K - $15K | 2015-08-10 | 2016-08-11 |
| Sheldon Whitehouse | Senate | RI | ▲ Buy | $1K - $15K | 2015-08-04 | 2016-08-11 |
| Sheldon Whitehouse | Senate | RI | ▲ Buy | $1K - $15K | 2015-07-10 | 2015-07-21 |
| Sheldon Whitehouse | Senate | RI | ▲ Buy | $15K - $50K | 2015-05-07 | 2015-08-12 |
| Sheldon Whitehouse | Senate | RI | ▲ Buy | $1K - $15K | 2015-04-07 | 2015-04-23 |
| Susan M. Collins | Senate | ME | ▼ Sell | $1K - $15K | 2014-07-23 | 2015-07-20 |
| Susan M. Collins | Senate | ME | ▼ Sell | $1K - $15K | 2014-03-27 | 2014-04-01 |